LBT-3627 is under clinical development by Longevity Biotech and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LBT-3627’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LBT-3627 overview

LBT-3627 is under development for the treatment of Parkinson's disease. The drug candidate is administered through oral route. It is developed based on hybridtide scaffold technology. It acts by targeting VPAC2. It was also under development for the treatment of spinal muscular atrophy ,diabetic neuropathy and multiple sclerosis.

Longevity Biotech overview

Longevity Biotech is a biopharmaceutical company that develops drug candidates. Its pipeline products include neuroscience – LBT-3627, diabetes – LBT-6030, fusion inhibitor – LBT-5001 and others. The company develops Hybridtides scaffold platform technology that offers therapeutic and diagnostic agents for human diseases. Longevity Biotech’s product LBT-3627 is a novel neuroprotective agent used in the treatment of disorders, and LBT-6030 is a gastric inhibitory polypeptide receptor and a dual agonist that targets the validated glucagon. The company operates in the US. Longevity Biotech is headquartered in Philadelphia, Pennsylvania, the US.

For a complete picture of LBT-3627’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.